10-Q: Profusa Reports Q2 Loss, Going Concern Doubt Amid Merger

Profusa, Inc. (formerly NorthView Acquisition Corp.) reported a significant net loss and working capital deficit for Q2 2025, raising substantial doubt about its ability to continue as a going concern, despite completing its merger with Profusa, Inc. and securing new financing.

Summary

• Profusa, Inc. (formerly NorthView Acquisition Corp.) completed its business combination with Profusa, Inc. on July 11, 2025, becoming a wholly-owned subsidiary.
• The company reported a net loss of $8,196,876 for the three months ended June 30, 2025, a substantial increase from a net loss of $397,487 for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $9,316,786, compared to $1,217,764 for the six months ended June 30, 2024.
• As of June 30, 2025, the company had only $1,751 in restricted cash and a working capital deficit of $15,492,554.
• Management expressed substantial doubt about the company's ability to continue as a going concern within one year from the financial statement issuance date.
• The company was delisted from Nasdaq on December 20, 2024, and its securities are now quoted on the OTC Market (Pink Markets) under symbols NVAC, NVACR, and NVACW.
• The company incurred significant non-cash losses from changes in fair value of warrant liabilities ($6,265,530 for six months ended June 30, 2025) and a convertible promissory note ($1,380,059 for six months ended June 30, 2025).
• A new Securities Purchase Agreement (SPA) was entered into on February 11, 2025, for senior secured convertible promissory notes up to $22,222,222, with an initial issuance of $10,000,000 principal for $9,000,000 purchase price at closing.
• Subsequent to the quarter end, on July 28, 2025, the company entered into another SPA for up to $100,000,000 in common stock sales to Ascent Partners Fund LLC.
• The company has an accrued excise tax liability of $1,952,662 as of June 30, 2025, related to share redemptions, and has accrued approximately $105,970 in interest and penalties for unpaid excise tax.
• Cash inflows from the business combination closing included $1.3 million from the Trust Account (net of redemptions) and a $9 million net PIPE convertible note.
• Cash outflows at closing included $3.4 million for marketing fees and vendor payments.
• Profusa stockholders are eligible for up to 3,875,000 additional earnout shares based on future stock price and revenue milestones, with revenue targets revised to $11,864,000 for fiscal year 2026 and consummation of the APAC Joint Venture by December 31, 2025.

Sentiment

Score: 2

Explanation: The sentiment is overwhelmingly negative due to significant net losses, a critical working capital deficit, explicit going concern doubt from management, Nasdaq delisting, and identified material weaknesses in internal controls. While the merger was completed and new financing secured, the terms of the financing are highly dilutive, and the overall financial health is precarious.

Positives

• The business combination with Profusa, Inc. was successfully consummated on July 11, 2025, transitioning the company from a blank check company to an operating entity.
• The company secured new financing through a Securities Purchase Agreement, issuing an initial $10,000,000 principal amount convertible note for $9,000,000 at closing.
• A subsequent Securities Purchase Agreement was entered into on July 28, 2025, providing access to up to $100,000,000 in additional capital through common stock sales.
• The company's stockholders approved the merger agreement, new Certificate of Incorporation, issuance of new common stock, election of new directors, and new employee incentive plans.

Negatives

• The company reported a significantly increased net loss of $9,316,786 for the six months ended June 30, 2025, compared to $1,217,764 for the same period in 2024.
• A substantial working capital deficit of $15,492,554 as of June 30, 2025, indicates severe liquidity issues.
• Management identified material weaknesses in internal controls over financial reporting, specifically regarding valuation of financial instruments, proper recording of accounts, and safeguarding of trust assets.
• The company was delisted from Nasdaq due to failure to complete its business combination by the deadline, resulting in trading on the less liquid OTC Market.
• Significant non-cash losses were incurred from changes in the fair value of warrant liabilities ($6,265,530) and a convertible promissory note ($1,380,059) for the six months ended June 30, 2025.
• An excise tax liability of $1,952,662 and accrued interest and penalties of $105,970 for unpaid excise tax represent a financial burden.
• The company has a substantial accumulated deficit of $22,510,739 as of June 30, 2025.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern within one year due to its significant working capital deficit and cash position.
• The company's securities were delisted from Nasdaq and now trade on the less liquid OTC Market, which may impact investor confidence and trading volume.
• Material weaknesses in internal controls over financial reporting could lead to financial misstatements and impact the reliability of financial reporting.
• The company faces potential interest and penalties on unpaid excise tax liability related to share redemptions.
• Future stock price and revenue milestones for earnout shares may not be achieved, impacting the value for Profusa stockholders.
• The convertible notes and securities purchase agreements contain complex terms, including conversion price adjustments based on future stock performance (down-round and MFN protections), which could lead to significant dilution for existing shareholders.
• The ability to draw on future tranches of the Securities Purchase Agreement is subject to conditions such as registration statement effectiveness, trading volume, and stock price thresholds, which may not be met.

Future Outlook

Management believes that factors continue to raise substantial doubt about the company's ability to continue as a going concern within one year. The company expects to incur expenses as a public company and for due diligence. Future earnout shares for Profusa stockholders are contingent on achieving specific stock price milestones ($12.50 and $14.50 per share) and revenue targets ($11,864,000 for FY2026, and consummation of the APAC Joint Venture by December 31, 2025). The company has also secured a new Securities Purchase Agreement for up to $100,000,000 in common stock sales, subject to various conditions including registration statement effectiveness and trading volume thresholds.

Management Comments

• Management believes that subsequent to the closing of the Merger, there continue to be factors which raise substantial doubt about the company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.
• Our internal controls did not detect an error in (i) the review of the convertible promissory notes valuation and warrant valuation, (ii) proper recording of accounts payable and accrued expenses, expensing or prepaid expenses, common stock subject to possible redemption, and the calculation of our income tax provision, and (iii) the proper safeguarding of trust assets and the monitoring process of the use of trust funds.

Industry Context

This filing reflects the challenges faced by Special Purpose Acquisition Companies (SPACs) in completing business combinations and maintaining Nasdaq listing requirements. The transition from a blank-check company to an operating entity (Profusa, Inc.) is a critical step, but the significant accumulated deficit, ongoing losses, and immediate going concern warning highlight the financial strain often associated with de-SPAC transactions, especially when redemptions are high and new capital is raised at potentially dilutive terms. The company's focus on medical devices and biotechnology (implied by the Profusa merger) places it in a capital-intensive industry where significant R&D and commercialization costs are expected, further exacerbating its current financial state.

Comparison to Industry Standards

• The company's net loss of $9.3 million for the first half of 2025 is substantial for a newly public entity, particularly one that has just completed a business combination. Compared to other de-SPACs in the biotechnology or medical device sector, such as Butterfly Network (BFLY) or Sema4 (SMFR, now GeneDx Holdings Corp.), which also experienced significant losses post-merger, Profusa's current financial state appears to be at the more distressed end of the spectrum, especially given its minimal cash balance and large working capital deficit.
• The delisting from Nasdaq and subsequent trading on the OTC Market is a significant negative deviation from industry standards for publicly traded companies, often leading to reduced liquidity and investor interest compared to peers listed on major exchanges like Nasdaq or NYSE.
• The identified material weaknesses in internal controls over financial reporting are a serious concern, indicating a lack of robust financial oversight. This contrasts sharply with the expectations for public companies, where strong internal controls are a fundamental requirement for reliable financial reporting and investor confidence. Many established biotech/medtech companies, even those in early stages, typically strive for and maintain effective internal controls to attract and retain institutional investment.
• The terms of the new capital raise, including the 10% Original Issue Discount (OID) on convertible notes and the 97% of lowest VWAP conversion price with down-round protection in the subsequent SPA, suggest highly dilutive financing terms. While common for distressed or early-stage companies in capital-intensive sectors, these terms are generally less favorable than those secured by more financially stable or mature companies in the medical device industry, such as Medtronic (MDT) or Abbott Laboratories (ABT), which can access capital at much lower costs and with less dilution.

Management Changes

Corporate Governance

Related Party Transactions

• Convertible Working Capital Promissory Note with NorthView Sponsor I, LLC: Principal outstanding of $1,919,796, fair value of $10,288,111 as of June 30, 2025. Repayment deferred to six months after the Closing.
• Administrative service fee: $50,000 owed to the Sponsor as of June 30, 2025, for office space, utilities, and administrative services, despite the agreement being terminated on June 30, 2023.
• Advances from Profusa: $1,299,040 owed to Profusa as of June 30, 2025, for operating expenses, due upon demand or at the completion of the Business Combination.

Stakeholder Impact

• Shareholders: Face significant dilution risk from convertible notes and future equity raises at potentially unfavorable prices. Existing shareholders have already experienced substantial redemptions and the company's delisting from Nasdaq.
• Employees: The successful completion of the merger provides a more stable corporate structure, but the going concern doubt could create uncertainty regarding job security and future prospects.
• Creditors: The significant increase in liabilities, particularly the convertible promissory note and excise tax payable, along with the going concern warning, indicate increased credit risk.
• Customers/Suppliers: While not directly addressed, the company's financial instability could impact its ability to invest in product development or maintain consistent supply chains, potentially affecting future customer relationships and supplier payments.

Next Steps

• The company needs to address the material weaknesses in its internal controls over financial reporting.
• The company will need to manage its liquidity and working capital deficit to continue operations.
• The company will need to achieve the stock price and revenue milestones to trigger the issuance of earnout shares to Profusa stockholders.
• The company may draw on additional tranches of the Securities Purchase Agreement with the institutional investor, subject to meeting specified conditions.
• The company may issue and sell common stock under the new Securities Purchase Agreement with Ascent Partners Fund LLC for up to $100,000,000.
• The company must address the unpaid excise tax liability and associated interest and penalties.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial net loss, a critical working capital deficit, and an explicit 'going concern' warning from management. The Nasdaq delisting significantly reduces liquidity and investor confidence. While the merger is complete and new financing secured, the terms of this financing are highly dilutive, and the company's ability to meet future obligations remains highly questionable. The identified material weaknesses in internal controls further compound the risk, suggesting fundamental operational issues. Given the precarious financial position and multiple red flags, a seasoned investor would likely recommend a strong sell to minimize further capital erosion.

Keywords

Profusa, NorthView Acquisition Corp, 10-Q, Quarterly Report, SEC Filing, Business Combination, Merger, Going Concern, Net Loss, Working Capital Deficit, Nasdaq Delisting, OTC Market, Convertible Notes, PIPE Financing, Warrant Liabilities, Excise Tax, Internal Controls, Earnout Shares, Biotechnology, Medical Devices